Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues
A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude…